Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Symptomatic, severe, or life-threatening drug-induced hepatic toxicity requires that all components of the drug regimen be stopped simultaneously, regardless of drug half-life
  • Discontinuation of emtricitabine, lamivudine, or tenofovir disoproxil fumarate in HBV/HIV–coinfected patients requires close monitoring and treatment to prevent flares
  • Treatment interruption of nevirapine for more than 2 weeks should have nevirapine reintroduced with a dose-escalation period

Action required